CDMOs Are Running Multi-Client Compliance Operations Under One Roof
Contract Development and Manufacturing Organizations (CDMOs) occupy a unique position in pharmaceutical supply chains. A mid-size CDMO may simultaneously hold cGMP manufacturing responsibilities for 15 to 30 client products at varying stages of development and commercial production—each governed by a separate Quality Technical Agreement (QTA) that defines roles, responsibilities, and quality standards between the sponsor and the CDMO.
According to IQVIA, the global CDMO market exceeded $220 billion in 2024 and is projected to grow at a compound annual rate of 7.8 percent through 2029, driven by pharma companies outsourcing manufacturing to reduce capital expenditures. As CDMOs add client programs, the administrative weight of managing multi-client quality agreements, change control workflows, and release testing documentation compounds accordingly.
For Quality Assurance departments already running lean to maintain cost competitiveness, this documentation burden is increasingly unsustainable without dedicated administrative support.
Quality Technical Agreement Tracking: Managing a Living Document Portfolio
A Quality Technical Agreement defines, for each client relationship, which quality activities are the responsibility of the CDMO versus the sponsor. These are living documents—they require review and reapproval whenever manufacturing processes change, when regulatory submissions are made, or on a defined periodic review cycle (typically every two to three years).
Tracking the status of 20 or more QTAs simultaneously—knowing which are in their review window, which require updates due to recent process changes, which are waiting for sponsor signature, and which have been filed to the appropriate quality management system—is a straightforward administrative task that does not require a QA degree. A virtual assistant can maintain a QTA master tracker, send renewal reminders 90 days before expiration, coordinate signature collection, and maintain the version-controlled archive.
Change Control Documentation: Coordinating Across Quality Teams
Under 21 CFR Parts 210 and 211 and ICH Q10 guidelines, any change to a validated manufacturing process, analytical method, facility, or equipment at a CDMO must go through a formal change control process. This process involves assessing the impact of the proposed change, obtaining approvals from both the CDMO's and the sponsor's quality teams, and documenting the change in the manufacturing site's quality management system.
For a multi-client CDMO, a single facility change—such as replacing a piece of manufacturing equipment or changing a cleaning agent—may require parallel change control coordination with ten or more sponsor quality teams simultaneously, each with their own approval timelines and documentation requirements.
A virtual assistant can own the coordination layer of this workflow: building and maintaining a change control tracker that shows the status of each sponsor's assessment and approval, sending reminder communications to sponsor quality contacts as deadlines approach, tracking the receipt of sponsor change control reference numbers, and ensuring that all documentation is organized for the CDMO's internal change control record closure.
Product Release Testing Coordination: The Final Compliance Checkpoint
Before a finished drug product batch can be released for distribution, all required release testing must be completed, Certificate of Analysis (CoA) documents must be generated and reviewed, and a quality review disposition package must be assembled for Qualified Person (QP) or Authorized Person review. For a CDMO running multiple concurrent production campaigns, coordinating the flow of samples to contract laboratories, tracking testing completion status, and assembling batch disposition packages is a significant ongoing administrative workload.
A VA can maintain the batch release tracker for each active campaign, coordinate sample shipment logistics to external contract labs, follow up on testing completion status, compile the release documentation package from CoA reports and batch record reviews, and route the completed package to the QA reviewer on schedule.
CDMOs and FDA-regulated drug manufacturers ready to scale administrative support for their quality operations can explore experienced candidates at Stealth Agents.
Sources
- IQVIA. Global CDMO Outlook 2024. iqvia.com
- FDA. 21 CFR Parts 210 and 211: cGMP for Finished Pharmaceuticals. fda.gov
- ICH. Q10: Pharmaceutical Quality System. ich.org